<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DEMSER- metyrosine capsule </strong><br>Aton Pharma, Inc.<br></p></div>
<h1>DEMSER<span class="Sup">®</span> (METYROSINE) Capsules</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">DEMSER<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a> (Metyrosine) is (–)-α-methyl-L-tyrosine or (α-MPT). It has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92&amp;name=demser-01.jpg"></div>
<p>Metyrosine is a white, crystalline compound of molecular weight 195. It is very slightly soluble in water, acetone, and methanol, and insoluble in chloroform and benzene. It is soluble in acidic aqueous solutions. It is also soluble in alkaline aqueous solutions, but is subject to oxidative degradation under these conditions.</p>
<p>DEMSER is supplied as capsules, for oral administration. Each capsule contains 250 mg metyrosine. Inactive ingredients are colloidal silicon dioxide, gelatin, hydroxypropyl cellulose, magnesium stearate, titanium dioxide, and FD&amp;C Blue 2.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>Registered trademark of ATON PHARMA, INC.<br>COPYRIGHT © 2007 ATON PHARMA, INC.<br>All rights reserved</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">DEMSER inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>, who produce excessive amounts of norepinephrine and epinephrine, administration of one to four grams of DEMSER per day has reduced catecholamine biosynthesis from about 35 to 80 percent as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after DEMSER is discontinued. In some patients the total excretion of catecholamines and catecholamine metabolites may be lowered to normal or near normal levels (less than 10 mg/24 hours). In most patients the duration of treatment has been two to eight weeks, but several patients have received DEMSER for periods of one to 10 years. Most patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> treated with DEMSER experience decreased frequency and severity of hypertensive attacks with their associated <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. In patients who respond, blood pressure decreases progressively during the first two days of therapy with DEMSER; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.</p>
<p>Metyrosine is well absorbed from the gastrointestinal tract. From 53 to 88 percent (mean 69 percent) was recovered in the urine as unchanged drug following maintenance oral doses of 600 to 4000 mg/24 hours in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> or <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span>. Less than 1% of the dose was recovered as catechol metabolites. These metabolites are probably not present in sufficient amounts to contribute to the biochemical effects of metyrosine. The quantities excreted, however, are sufficient to interfere with accurate determination of urinary catecholamines determined by routine techniques.</p>
<p>Plasma half-life of metyrosine determined over an 8-hour period after single oral doses was 3-3.7 hours in three patients.</p>
<p>For further information, refer to: Sjoerdsma, A.; Engelman, K.; Waldman, T.A.; Cooperman, L.H.; Hammond, W.G.: <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">Pheochromocytoma</span>: Current concepts of diagnosis and treatment, Ann. Intern. Med. 65: 1302-1326, Dec. 1966.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">DEMSER is indicated in the treatment of patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> for:</p>
<p>1. Preoperative preparation of patients for surgery</p>
<p>2. Management of patients when surgery is contraindicated</p>
<p>3. Chronic treatment of patients with malignant <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span>.</p>
<p>DEMSER is not recommended for the control of <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">DEMSER is contraindicated in persons known to be hypersensitive to this compound.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Maintain Fluid Volume During and After Surgery</h2>
<p class="First">When DEMSER is used preoperatively, alone or especially in combination with alpha-adrenergic blocking drugs, adequate intravascular volume must be maintained intraoperatively (especially after tumor removal) and postoperatively to avoid <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and decreased perfusion of vital organs resulting from <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> and expanded volume capacity. Following tumor removal, large volumes of plasma may be needed to maintain blood pressure and central venous pressure within the normal range.</p>
<p>In addition, life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. During surgery, patients should have continuous monitoring of blood pressure and electrocardiogram.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>Intraoperative Effects</h2>
<p class="First">While the preoperative use of DEMSER in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> is thought to decrease intraoperative problems with blood pressure control, DEMSER does not eliminate the danger of hypertensive crises or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> during manipulation of the tumor, and the alpha-adrenergic blocking drug, phentolamine, may be needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>Interaction with Alcohol</h2>
<p class="First">DEMSER may add to the sedative effects of alcohol and other CNS depressants, e.g., hypnotics, sedatives, and tranquilizers. (See <a href="#P-Information_for_Patients">PRECAUTIONS, Information for Patients</a> and <a href="#P-Drug_Interactions">Drug Interactions</a>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="P-General"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3>Metyrosine <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span></h3>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> and <span class="product-label-link" type="condition" conceptid="79873" conceptname="Urolith">urolithiasis</span> have been found in dogs treated with DEMSER (Metyrosine) at doses similar to those used in humans, and <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> has also been observed in a few patients. To minimize the risk of <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>, patients should be urged to maintain water intake sufficient to achieve a daily urine volume of 2000 mL or more, particularly when doses greater than 2 g per day are given. Routine examination of the urine should be carried out. Metyrosine will crystallize as needles or rods. If metyrosine <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> occurs, fluid intake should be increased further. If <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span> persists, the dosage should be reduced or the drug discontinued.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3>Relatively Little Data Regarding Long-term Use</h3>
<p class="First">The total human experience with the drug is quite limited and few patients have been studied long-term. Chronic animal studies have not been carried out. Therefore, suitable laboratory tests should be carried out periodically in patients requiring prolonged use of DEMSER and caution should be observed in patients with impaired hepatic or renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="P-Information_for_Patients"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">When receiving DEMSER, patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a motor vehicle or operating machinery. DEMSER may have additive sedative effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, and tranquilizers.</p>
<p>Patients should be advised to maintain a liberal fluid intake. (See <a href="#P-General">PRECAUTIONS, General</a>.)</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="P-Drug_Interactions"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.</p>
<p>Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects. (See <a href="#WARNINGS">WARNINGS</a> and <a href="#P-Information_for_Patients">PRECAUTIONS, Information for Patients</a>.)</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-6.4"></a><p></p>
<h2>Laboratory Test Interference</h2>
<p class="First">Spurious increases in urinary catecholamines may be observed in patients receiving DEMSER due to the presence of metabolites of the drug.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenic studies in animals and studies on mutagenesis and impairment of fertility have not been performed with metyrosine.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.6.1"></a><p></p>
<h3>Pregnancy Category C</h3>
<p class="First">Animal reproduction studies have not been conducted with DEMSER. It is also not known whether DEMSER can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. DEMSER should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether DEMSER is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when DEMSER is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 12 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of DEMSER did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Central Nervous System</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>Sedation:</h3>
<p class="First">The most common adverse reaction to DEMSER is moderate to severe sedation, which has been observed in almost all patients. It occurs at both low and high dosages. Sedative effects begin within the first 24 hours of therapy, are maximal after two to three days, and tend to wane during the next few days. Sedation usually is not obvious after one week unless the dosage is increased, but at dosages greater than 2000 mg/day some degree of sedation or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> may persist.</p>
<p>In most patients who experience sedation, temporary changes in sleep pattern occur following withdrawal of the drug. Changes consist of <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> that may last for two or three days and feelings of increased alertness and ambition. Even patients who do not experience sedation while on DEMSER may report symptoms of psychic stimulation when the drug is discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.2"></a><p></p>
<h3>Extrapyramidal Signs:</h3>
<p class="First">Extrapyramidal signs such as <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">drooling</span>, speech difficulty, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> have been reported in approximately 10 percent of patients. These occasionally have been accompanied by <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span> and frank <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> and <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">Psychic Disturbances</span>:</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> and <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> such as <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> may occur. These effects seem to be dose-dependent and may disappear with reduction of dosage.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> occurs in about 10 percent of patients and may be severe. Anti-diarrheal agents may be required if continuation of DEMSER is necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First">Infrequently, slight <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the breast, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span>, decreased <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> or failure of ejaculation may occur. <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> (see <a href="#PRECAUTIONS">PRECAUTIONS</a>) and transient <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> have been observed in a few patients. Hematologic disorders (including <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>), increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> levels, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span> have been reported rarely.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Signs of metyrosine overdosage include those central nervous system effects observed in some patients even at low dosages.</p>
<p>At doses exceeding 2000 mg/day, some degree of sedation or feeling of <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> may persist. Doses of 2000-4000 mg/day can result in <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> or <span class="product-label-link" type="condition" conceptid="4308866" conceptname="Agitated depression">agitated depression</span>, neuromuscular effects (including fine <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> of the hands, gross <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> of the trunk, tightening of the jaw with <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and decreased <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span> with <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p>Reduction of drug dose or cessation of treatment results in the disappearance of these symptoms.</p>
<p>The acute toxicity of metyrosine was 442 mg/kg and 752 mg/kg in the female mouse and rat respectively.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended initial dosage of DEMSER for adults and children 12 years of age and older is 250 mg orally four times daily. This may be increased by 250 mg to 500 mg every day to a maximum of 4.0 g/day in divided doses. When used for preoperative preparation, the optimally effective dosage of DEMSER should be given for at least five to seven days.</p>
<p>Optimally effective dosages of DEMSER usually are between 2.0 and 3.0 g/day, and the dose should be titrated by monitoring clinical symptoms and catecholamine excretion. In patients who are hypertensive, dosage should be titrated to achieve normalization of blood pressure and control of clinical symptoms. In patients who are usually normotensive, dosage should be titrated to the amount that will reduce urinary metanephrines and/or vanillylmandelic acid by 50 percent or more.</p>
<p>If patients are not adequately controlled by the use of DEMSER, an alpha-adrenergic blocking agent (phenoxybenzamine) should be added.</p>
<p>Use of DEMSER in children under 12 years of age has been limited and a dosage schedule for this age group cannot be given.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Capsules DEMSER, 250 mg, are opaque, two-toned blue capsules coded Aton 305 on one side and DEMSER on the other. They are supplied as follows:</p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">NDC</span> 25010-305-15 bottles of 100.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1></h1>
<p class="First">Distributed by:<br><span class="Bold">ATON PHARMA</span><br>Lawrenceville<br>NJ 08648<br>USA</p>
<p>Manufactured by:<br>Pharmaceutics International, Inc.<br>10819 Gilroy Road<br>Hunt Valley, MD 21031 USA</p>
<p>Issued February 2010<br>8834-00</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 250 mg Capsule Label</h1>
<p class="First"><span class="Bold">Demser<span class="Sup">®</span> 250 mg<br>(Metyrosine)</span></p>
<p><span class="Bold">NDC</span> 25010-305-15</p>
<p><span class="Bold">Distributed by:<br>ATON PHARMA, INC.<br>LAWRENCEVILLE, NJ 08648, USA</span></p>
<p><span class="Bold">Rx only</span></p>
<p>USUAL ADULT DOSAGE:<br>See accompanying circular.</p>
<p>This is a bulk package and not intended<br>for dispensing.</p>
<p>Package not child resistant.</p>
<p>Dispense in a well-closed container.</p>
<p><span class="Bold">100</span> Capsules</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 250 mg Capsule Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92&amp;name=demser-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DEMSER 		
					</strong><br><span class="contentTableReg">metyrosine capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25010-305</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>metyrosine</strong> (metyrosine) </td>
<td class="formItem">metyrosine</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue No. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (two-toned blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Aton;305;DEMSER</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25010-305-15</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017871</td>
<td class="formItem">10/03/1979</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Aton Pharma, Inc.
							(795419675)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmaceutics International, Inc.</td>
<td class="formItem"></td>
<td class="formItem">878265586</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Draxis Pharma, Inc. (Produits Pharmaceutiques Specialises Draxis Inc.)</td>
<td class="formItem"></td>
<td class="formItem">243604761</td>
<td class="formItem">PACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>90965385-d7cf-4d26-8ed6-7c9b2558324d</div>
<div>Set id: 32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92</div>
<div>Version: 3</div>
<div>Effective Time: 20101210</div>
</div>
</div> <div class="DistributorName">Aton Pharma, Inc.</div></p>
</body></html>
